#Israel #Tel Aviv #BioLineRx #GLIX1 #Hemispherian

BioLineRx and Hemispherian Showcase GLIX1 Research at Neuro-Oncology Meeting

BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS are set to present groundbreaking research on GLIX1 at the 31st Society for Neuro-Oncology (SNO) Annual Meeting and Education Day, scheduled for November 12-15, 2026, in Philadelphia, Pennsylvania. These two abstracts will provide a unique glimpse into the potential of GLIX1, a novel therapeutic agent, in treating aggressive brain tumors like glioblastoma.

GLIX1: An Overview

GLIX1 is a first-in-class oral small molecule that acts as a TET2 activator, targeting the DNA damage response in glioblastoma and other solid tumors. The compound's development is being pushed forward in partnership between BioLineRx and Hemispherian, focusing on delivering life-changing therapies in oncology, particularly for patients suffering from high-grade glioma.

Presentation Highlights

The presentations at the SNO will cover two significant aspects of GLIX1 research:
1. Preclinical Research: The first presentation will showcase preclinical research results, exploring the efficacy of GLIX1 across various glioblastoma models. The findings highlight the compound's potent anti-tumor activity, demonstrated through both orthotopic patient-derived xenograft (PDX) models as well as subcutaneous models resistant to temozolomide (TMZ).
- Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS
- Format: Poster presentation
- Date/Time: Friday, November 13, 2026, from 7:30 PM to 9:30 PM EST
- Location: Pennsylvania Convention Center, Exhibit Halls D and E

2. Clinical Trial Design: The second presentation will detail the ongoing Phase 1/2a clinical trial evaluating GLIX1's safety and efficacy in patients with recurrent or progressive high-grade glioma. This trial represents a significant step toward bringing innovative therapies to market for challenging neuro-oncological conditions.
- Presenter: Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine
- Format: Poster presentation
- Date/Time: Same as above
- Location: Similar venue

The Society for Neuro-Oncology (SNO)

The SNO Annual Meeting is a premier gathering for professionals focusing on brain tumor research and treatment advancements. It provides a platform for clinicians and scientists to exchange innovative ideas and the latest findings. More information about the meeting can be found on their official website, which details agenda and participating speakers.

About Hemispherian

Hemispherian AS is a forward-thinking pharmaceutical company based in Oslo, Norway. It specializes in developing cutting-edge small molecule therapies aimed at treating cancer. The collaboration with BioLineRx for GLIX1 showcases their commitment to addressing unmet medical needs in oncology. The company engages with significant academic and clinical institutions globally to enhance its research capabilities and solidify its product development pipeline.

About BioLineRx

BioLineRx, a biopharmaceutical leader based in Tel Aviv, is dedicated to creating transformative therapies for oncology and rare diseases. The company’s flagship product, GLIX1, is a core component of its strategy to advance therapeutic solutions in complex medical conditions such as glioblastoma. Additionally, BioLineRx’s first approved drug, APHEXDA® (motixafortide), is already being commercialized through strategic collaborations worldwide.

Future Prospects

Both BioLineRx and Hemispherian remain optimistic about the potential impact of GLIX1 in the field of oncology. The upcoming presentations at the SNO Annual Meeting symbolize a vital step in their mission to provide new hope for patients battling aggressive cancers. Stakeholders are eagerly looking forward to the outcomes of these studies and their implications on future treatment pathways.

Stay tuned for further updates as these companies share their pioneering research with the global neuro-oncology community.